Aytu Biopharma (AYTU) Receivables - Other (2021 - 2025)

Aytu Biopharma (AYTU) has 3 years of Receivables - Other data on file, last reported at $3.1 million in Q2 2025.

• On a quarterly basis, Receivables - Other fell 50.0% year-over-year to $3.1 million in Q2 2025; TTM through Jun 2025 was $3.1 million, a 50.0% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, down 50.0% from the prior year.
• Receivables - Other for Q2 2025 stood at $3.1 million, down from $4.3 million in the prior quarter.
• Over the last five years, Receivables - Other for AYTU reached as high as $6.2 million in Q2 2024 and fell as low as $9000.0 in Q3 2021.
• Historically, Receivables - Other has averaged $3.6 million across 3 years, with a median of $4.3 million in 2025.
• On a YoY basis, Receivables - Other climbed as much as 50.0% in 2025 and fell as far as 50.0% in 2025.
• Year by year, Receivables - Other stood at $9000.0 in 2021, then soared by 64344.44% to $5.8 million in 2024, then plunged by 46.55% to $3.1 million in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $3.1 million in Q2 2025, $4.3 million in Q1 2025, and $5.8 million in Q4 2024.